Cognition Therapeutics Announces $30 Million Registered Direct Offering of Common Stock
- The offering was made to two new fundamental institutional investors -
Related Questions
How will the $30 million direct offering dilute existing shareholders and affect the EPS outlook?
What are the terms and pricing of the offering compared to recent market prices and similar deals in the biotech sector?
Who are the two new institutional investors and what does their involvement indicate about confidence in Cognition Therapeutics' pipeline?